Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Aug 25, 2016; 8(16): 546-552
Published online Aug 25, 2016. doi: 10.4253/wjge.v8.i16.546
Endoscopic applications of cryospray ablation therapy-from Barrett’s esophagus and beyond
Jayaprakash Sreenarasimhaiah
Jayaprakash Sreenarasimhaiah, Department of Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States
Author contributions: Sreenarasimhaiah J designed, composed, and edited the entire manuscript; all pictures were also from the direct work of Sreenarasimhaiah J; the manuscript was written completely by this author alone.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jayaprakash Sreenarasimhaiah, MD, Department of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, MC 9083, Dallas, TX 75390, United States. jayaprakash.sree@yahoo.com
Telephone: +1-214-6450595
Received: March 26, 2016
Peer-review started: March 27, 2016
First decision: May 17, 2016
Revised: June 1, 2016
Accepted: June 27, 2016
Article in press: June 29, 2016
Published online: August 25, 2016
Processing time: 149 Days and 23.1 Hours
Core Tip

Core tip: The current standard of care in treatment of dysplastic Barrett’s esophagus is endoscopic ablation. Cryospray ablation, the newest modality can achieve complete eradication of dysplasia and intestinal metaplasia in over 90% of patients. Unlike other endoscopic methods, its unique mechanisms and depth of injury enable successful ablation of early esophageal carcinoma, palliative debulking of advanced carcinoma and reduction of tumor ingrowth into stents. The applications of cryospray ablation beyond the esophagus include control of bleeding from gastric antral vascular ectasia, portal hypertensive gastropathy, and radiation proctitis. This modality continues to evolve as an important tool of therapeutic endoscopy.